| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/25/2004 | EP1448232A1 Anti-proliferative composition |
| 08/25/2004 | EP1448231A1 Topical delivery of codrugs |
| 08/25/2004 | EP1448228A2 Management of postoperative pain |
| 08/25/2004 | EP1448227A2 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization |
| 08/25/2004 | EP1448220A2 Antiphlogistic agent and the use thereof |
| 08/25/2004 | EP1448219A1 Antiglaucomatous agent and use thereof |
| 08/25/2004 | EP1448217A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 08/25/2004 | EP1448215A2 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections |
| 08/25/2004 | EP1448214A2 Ginger extract preparation |
| 08/25/2004 | EP1448213A2 Plant derived or derivable material with appetite suppressant activity |
| 08/25/2004 | EP1448209A2 A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 08/25/2004 | EP1448208A2 Composition based on diosgenin ester for topical use |
| 08/25/2004 | EP1448207A1 Dosage regimen and pharmaceutical composition for emergency contraception |
| 08/25/2004 | EP1448206A1 Estrogen receptor beta-selective agonists for anti-catabolic therapy in an aging organism |
| 08/25/2004 | EP1448205A2 Combinations for the treatment of immunoinflammatory disorders |
| 08/25/2004 | EP1448204A1 New dry and aqueous epinastine-syrup-formulation |
| 08/25/2004 | EP1448203A1 Pharmaceutical formulations comprising substituted xanthine compounds |
| 08/25/2004 | EP1448202A1 Combination of a pde4 or pde3/4 inhibitor and an anti-rheumatic drug |
| 08/25/2004 | EP1448201A2 Use of n-(indolcarbonyl-)piperazine derivatives |
| 08/25/2004 | EP1448200A2 (4-phenyl)piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 08/25/2004 | EP1448199A1 Benzimidazoles useful as protein kinase inhibitors |
| 08/25/2004 | EP1448198A1 Nicotin-or isonicotin benzothiazole derivatives |
| 08/25/2004 | EP1448196A1 Benzothiazole derivatives as adenosine receptor ligands |
| 08/25/2004 | EP1448195A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 08/25/2004 | EP1448194A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| 08/25/2004 | EP1448193A1 Therapeutic compounds for treating dyslipidemic conditions |
| 08/25/2004 | EP1448192A2 Novel methods of treating local fungal and bacterial infections |
| 08/25/2004 | EP1448191A1 Ilk inhibitors for the treatment of renal disease |
| 08/25/2004 | EP1448190A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 08/25/2004 | EP1448189A2 Use of bisindolmaleimide and gemcitabine for the treatment of cancer |
| 08/25/2004 | EP1448188A1 Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells |
| 08/25/2004 | EP1448186A1 Medicament for the treatment of viral skin and tumour diseases |
| 08/25/2004 | EP1448185A1 Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties |
| 08/25/2004 | EP1448184A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease |
| 08/25/2004 | EP1448183A2 Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| 08/25/2004 | EP1448182A1 Pharmaceutical compositions and methods for administering ep 2 receptor selective agonists |
| 08/25/2004 | EP1448181A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 08/25/2004 | EP1448180A1 Para-amino benzoic acids as integrin antagonists |
| 08/25/2004 | EP1448179A1 Substituted bicyclo 3.3.1 nonan-2,4,9-triones as pharmaceutical active ingredients |
| 08/25/2004 | EP1448178A1 Prevention of miscarriage with immunomodulating non-endogenous gestagen compounds |
| 08/25/2004 | EP1448176A2 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 08/25/2004 | EP1448175A1 Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate |
| 08/25/2004 | EP1448174A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 08/25/2004 | EP1448173A2 A process for manufacture of a sustained release pharmaceutical composition containing microbeads of trimetazidine dihydrochloride |
| 08/25/2004 | EP1448171A2 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 08/25/2004 | EP1448169A1 Method for improving dissolution of poorly dispersible medicaments |
| 08/25/2004 | EP1448168A1 Pharmaceutical formulation comprising bicalutamide |
| 08/25/2004 | EP1448167A1 New use of ethoxylated phytosterols and phytostanols |
| 08/25/2004 | EP1448166A1 Controlled release polymeric compositions of bone growth promoting compounds |
| 08/25/2004 | EP1448155A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
| 08/25/2004 | EP1448152A2 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 08/25/2004 | EP1448151A1 Dosage form, device and methods of treatment |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1448127A1 Compositions for the treatment of infectious diseases |
| 08/25/2004 | EP1448089A2 Devices and methods for the restoration of a spinal disc |
| 08/25/2004 | EP1448051A2 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 08/25/2004 | EP1372641A4 Enteral formulation |
| 08/25/2004 | EP1366048B1 Pyrazolopyridine derivatives |
| 08/25/2004 | EP1360957A4 Vitamin/mineral complex |
| 08/25/2004 | EP1347963B1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 08/25/2004 | EP1343764B1 Urea and urethane derivatives as integrin inhibitors |
| 08/25/2004 | EP1311277A4 Methods of modulating fibrosis |
| 08/25/2004 | EP1299132B1 Limiting the presence of microorganisms using polymer-bound metal-containing compositions |
| 08/25/2004 | EP1289506B1 Process for producing a stable micronized composition of formoterol with a glucocorticosteroid |
| 08/25/2004 | EP1278728B1 Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders |
| 08/25/2004 | EP1270555B1 Method for oxidizing a thioether group into a sulfoxide group |
| 08/25/2004 | EP1244663B1 Compounds and methods for the treatment of pain |
| 08/25/2004 | EP1228235B1 Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins |
| 08/25/2004 | EP1212067A4 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 08/25/2004 | EP1169337B1 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 08/25/2004 | EP1156044B1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
| 08/25/2004 | EP1150977B1 Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| 08/25/2004 | EP1149069B1 Phenylglycine derivatives |
| 08/25/2004 | EP1135026A4 Novel methods of protecting plants from pathogens |
| 08/25/2004 | EP1094790B1 Sustained release pharmaceutical preparation comprising phenytoin sodium |
| 08/25/2004 | EP1087963B1 Inhibitors of glycogen synthase kinase 3 |
| 08/25/2004 | EP1086080B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics |
| 08/25/2004 | EP1083903B1 Bridged indenopyrrolocarbazoles |
| 08/25/2004 | EP1083881B1 LIPOSOME COMPOSITIONs containing a quinolone derivative AND their use as antibacterial agents |
| 08/25/2004 | EP1082138B1 Texaphyrin conjugates and uses thereof |
| 08/25/2004 | EP1025094B1 Substituted indan derivatives |
| 08/25/2004 | EP1003553B1 The use of angiostatic steroids in photodynamic therapy |
| 08/25/2004 | EP0983072B1 Use of fructan for the manufacture of a medicament for the prevention and treatment of colon cancer |
| 08/25/2004 | EP0973743B1 Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| 08/25/2004 | EP0883616B1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| 08/25/2004 | EP0881906B1 Pharmaceutical composition for immunomodulation based on peptides and adjuvants |
| 08/25/2004 | EP0873424B1 Metastasis inducing dna's |
| 08/25/2004 | EP0854869B1 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 08/25/2004 | EP0852463A4 Myogenic differentiation of human mesenchymal stem cells |
| 08/25/2004 | EP0830130B1 Tnf-alpha converting enzyme |
| 08/25/2004 | EP0810853B1 Aerosols containing nanoparticle dispersions |
| 08/25/2004 | CN1524125A 化合物 Compound |
| 08/25/2004 | CN1524088A A virus causing respiratory tract illness in susceptible mammals |
| 08/25/2004 | CN1524085A Oligose ,sulfating product and oligose cluster and its uses |
| 08/25/2004 | CN1524082A Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl idase inhibitors for the treatment or prevention of diabetes |
| 08/25/2004 | CN1524081A Pyrimidine derivatives for inhibition of cell proliferation |
| 08/25/2004 | CN1524080A Phthalatyinone-piperidino-derivatives as pde4 inhibitors |
| 08/25/2004 | CN1524079A Novel sulfamides and their use as endothelin receptor antagonists |
| 08/25/2004 | CN1524078A Antagonists of mcp-1 function and methods of use thereof |
| 08/25/2004 | CN1524077A Therapeutic chroman compounds |